about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIsThe use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: a case study.Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.Deep sequencing reveals microRNAs predictive of antiangiogenic drug responseSunitinib for the treatment of metastatic renal cell carcinoma.A case series of embryonal rhabdomyosarcoma of the head and neck in adults.Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine.Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab.Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.Characterizing the outcomes of metastatic papillary renal cell carcinoma.Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib.Ciprofloxacin-induced hypersensitivity vasculitis.Molecular subtypes and prognosis in RCC.Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.Multicystic pulmonary metastases of endometrial carcinoma.P17.22LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA.Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
P50
Q21183974-A61FB3B1-3CE0-43F6-9357-3E38F261E84DQ28584533-54E0E971-1941-4995-A73F-C577F02DF89CQ30374367-7879F2E1-D6C7-4E7D-B528-8EA4B45B89C4Q35188542-425DE893-5B0B-4C18-BD28-7B9D6E468278Q35524465-A249E0DF-1C0B-43A9-9D92-4C5FA688A5F8Q35530473-A987BEB8-5F82-455F-B32A-27DACBF3CCE4Q36056167-EC3793A5-5A76-4C83-901E-A5BC56A9178AQ36093975-1F36C4A8-303A-4AEA-8977-8B548A52DF01Q36256382-F8B21D1C-7191-4467-8488-DD20EF8945CEQ36385639-B684E364-2263-495E-A155-A12707A1FFA8Q36750660-C4455CFC-B58A-4D37-BF09-9C306AC472D0Q36797096-5F606F05-99E4-4B0C-AAEB-17F6BA466A4DQ37040692-121CC718-60AF-4243-A6A9-76C5FF63C087Q37277227-64F51F24-003B-49F6-BEC9-B4A1FD3883EFQ37785348-8E724564-DCD8-41E4-A89A-6E9FD8B9914BQ37832489-8664486C-525F-40A3-9C77-97BFCE525677Q38161531-842E76B3-3580-4E0C-BA31-D6DCD2EF1A7FQ38196855-4D11CA5C-80D3-4AF7-8AC5-C43E89FDAEF6Q38988249-77495A73-F19B-4FFA-AEDF-8664051DE36CQ39221843-25CD0D7F-36AD-4122-B07C-64866199435BQ39563373-3EB922F2-3187-4BA1-8777-7A7000F3A4D4Q39569027-39B12F60-25BF-4390-9CC9-2CDBCB6F82BDQ39601152-C6C024D9-857B-4A6E-AB7A-69CEA35154E0Q40329861-1C47DFDE-D3F5-4E10-99F4-6E98C35E582EQ41590541-B46746DB-F712-45F1-8617-0129560903A7Q41735562-DD504AE9-0DE7-4DEB-8B1A-F1878B9BCE23Q42172414-CE8D3128-96B2-4961-902F-556ADAD14BF1Q42200105-9FBD86E1-7B8D-423B-961D-991786003D48Q42282163-D0DFD369-BFBC-48FD-91F9-CBB40217C703Q42558838-1C14980E-5F80-44A5-9F9C-B102EAF0206BQ43299363-C43B99FA-6649-4D08-ABD6-B8DEFB640598Q43445981-ABB9742F-7526-4689-8B1B-6F9F90A0FF88Q43978025-6A4924AA-7976-4D21-8E52-0503BA495944Q45778660-33580BCA-25EE-4D03-942B-73BC2FAF3731Q46183963-2D2D400C-89B9-473B-8A29-DAF00D053435Q46245352-9BC82FF0-1375-4B7A-8183-19B568F5B22CQ46883570-54340C08-5303-4E7E-88A3-11EEB56F6D7BQ46884807-53538D5A-86EB-48D6-A327-C3EC2AF7498EQ47325841-17285A7A-7FB8-49B7-909F-011D16BF172CQ47672449-F640C868-D777-417D-A735-B0F112B1FF86
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Benoit Beuselinck
@ast
Benoit Beuselinck
@en
Benoit Beuselinck
@es
Benoit Beuselinck
@nl
Benoit Beuselinck
@sl
type
label
Benoit Beuselinck
@ast
Benoit Beuselinck
@en
Benoit Beuselinck
@es
Benoit Beuselinck
@nl
Benoit Beuselinck
@sl
prefLabel
Benoit Beuselinck
@ast
Benoit Beuselinck
@en
Benoit Beuselinck
@es
Benoit Beuselinck
@nl
Benoit Beuselinck
@sl
P106
P21
P31
P496
0000-0001-7427-9102